Core Insights - Sanara MedTech Inc. has launched a pilot program through its subsidiary Tissue Health Plus (THP) aimed at providing value-based wound care solutions for chronic wounds across six states [1][2] - The THP technology platform will serve as a Wound Care Operating System for a provider group, utilizing Co-Pilot software to standardize patient care and streamline administrative processes [2] - The pilot program is expected to validate and optimize the THP technology platform through real-world patient encounters, with plans for expansion to additional practitioners and locations [2] Company Overview - Sanara MedTech Inc. focuses on developing and commercializing technologies to improve clinical outcomes and reduce healthcare costs in surgical and chronic wound markets [4] - The company markets a range of surgical and wound care products primarily in the North American market, including CellerateRX Surgical Activated Collagen and various antimicrobial solutions [4][5] - THP aims to transform the $100+ billion wound care market by addressing gaps in chronic wound care, with a goal of improving healing rates to over 85% and reducing total care costs by more than 25% [3] Technology and Innovation - THP's platform combines AI-powered clinical decision support, virtual care coordination, and an integrated provider network to deliver personalized wound care [3] - The pilot program is part of a broader strategy to engage with payers and financial partners to support the implementation of THP's value-based care solutions [2][3]

MONSEY, N.Y., July 14, 2025 (GLOBE NEWSWIRE) --  The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Monogram Technologies, Inc. (Nasdaq: MGRM) (“Monogram”) to Zimmer Biomet for an upfront payment of $4.04 per share in cash, and a non-tradeable contingent value right (CVR) entitling the holder to receive up to $12.37 per share in cash if certain product development, regulatory, and revenue milestones are achieved through 2030. At least two investors have already express ...

Core Insights - Firefly Neuroscience, Inc. is collaborating with Heidelberg University Hospital to study the neurophysiological impact of 15q13.3 copy number variants (CNVs) [1][3] - The study utilizes Firefly's FDA-cleared technology to analyze EEG data from 30 subjects, aiming to uncover insights into brain function related to rare genetic conditions [2][3] - The collaboration reflects a commitment to advancing precision neuroscience and aims to bridge the gap between genotype and phenotype for better patient care [3] Company Overview - Firefly is an AI company focused on improving brain health outcomes for patients with neurological and mental disorders, with a proprietary technology called Brain Network Analytics (BNA™) [7][8] - The company has built a comprehensive database of brain wave tests over the past 15 years and has achieved FDA clearance for its technology [7][8] - Firefly is targeting pharmaceutical companies and medical practitioners for the commercial launch of its BNA™ technology [7] Study Objectives - The study aims to identify electrophysiological biomarkers associated with 15q13.3 CNVs [6] - It will characterize neurocognitive profiles linked to deletions versus duplications of the chromosomal region [6] - The research supports future diagnostic and therapeutic strategies for neurodevelopmental disorders [6]

Bringing together complementary technologies to serve high-volume testing in attractive and regulated end-markets: The combined company will have best-in-class liquid chromatography, mass spectrometry, flow cytometry, and diagnostic solutions, doubling Waters' total addressable market to approximately $40 billion. Increasing annual recurring revenue in high-quality applications: Over 70% of the combined company's revenue is expected to be recurring annually and over half of instrument revenue is expected to ...

Investment Rating - The report maintains a "Buy" rating for Boston Scientific (BSX), Edwards Lifesciences (EW), GE Healthcare (GEHC), Intuitive Surgical (ISRG), and Haemonetics (HAE), while downgrading Tandem Diabetes (TNDM) to "Sell/High Risk" from "Neutral/High Risk" [1][5][20]. Core Insights - The MedTech sector has shown resilience against healthcare headwinds, with a focus on returning to fundamentals and several catalysts expected to drive momentum in the second half of 2025 [1][9]. - The S&P Equipment and Supplies Index has outperformed the broader market, with a year-to-date increase of 7.2%, while relative P/E multiples remain below historical averages [2][12]. - Key upcoming catalysts include product launches and data readouts from various companies, which are anticipated to influence stock performance positively [3][10][11]. Summary by Sections Market Overview - The MedTech industry has largely absorbed tariff impacts, with a weakening USD providing additional support [1][9]. - The S&P 500 is up 6.2% year-to-date, while the S&P Equipment and Supplies Index has increased by 7.2% [2][12]. Company-Specific Insights - Boston Scientific (BSX) is expected to benefit from Farapulse and new product launches, projecting a revenue increase of 80.1% year-over-year in 2Q25 [3][10]. - Edwards Lifesciences (EW) anticipates pivotal data releases and the reopening of TAVR NCD, which could enhance its market position [3][10]. - Intuitive Surgical (ISRG) plans a broad launch of its DV5 system, which is expected to drive stock performance [4][10]. - Haemonetics (HAE) has been upgraded to "Buy" due to improved guidance and revenue growth expectations [5][20]. - Tandem Diabetes (TNDM) faces competitive pressures, leading to its downgrade to "Sell/High Risk" [5][20]. Valuation and Target Prices - Target prices have been adjusted for several companies, with BSX at $125, EW at $95, GEHC at $86, and ISRG at $650 [20][21]. - The report highlights that the relative P/E multiple for the MedTech sector is currently at 1.14x, below historical averages, indicating potential undervaluation [2][12][14].

Company Overview - BioStem Technologies, Inc. is a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care [5] - The company utilizes its proprietary BioREtain processing method to maintain growth factors and preserve tissue structure in its allografts [5] Market Position and Opportunities - Jason Matuszewski, Chairman and CEO, will present BioStem's current position in the chronic wound care market and key opportunities for growth at the Advanced Wound Care Summit on July 15, 2025 [1] - The company aims to drive continued growth in its core allograft business while pursuing opportunities to expand its portfolio across the continuum of care [8] Event Details - The Advanced Wound Care Summit will take place from July 15 to 17, 2025, bringing together global leaders in wound care innovation and clinical research [3] - The summit will feature keynote presentations, interactive panels, and strategic networking opportunities to address unmet needs in chronic wound management [3] Quality and Compliance - BioStem's quality management systems and standard operating procedures are accredited by the American Association of Tissue Banks (AATB) and adhere to Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP) [6] - The company's products are processed at an FDA registered and AATB accredited site in Pompano Beach, Florida [6]

Core Viewpoint - InMode Ltd. is revising its full-year revenue guidance for 2025 due to ongoing market weakness and uncertainty in the U.S. economic outlook, with preliminary second-quarter revenue expected to be between $95.4 million and $95.5 million [3][7]. Financial Results - The company anticipates second-quarter 2025 revenue in the range of $95.4 million to $95.5 million [7]. - The non-GAAP gross margin for the second quarter of 2025 is expected to be between 79% and 80% [7]. - Full-year 2025 revenue guidance has been revised to a range of $365 million to $375 million, down from the previous guidance of $395 million to $405 million [3][7]. Conference Call Details - A conference call to discuss the second-quarter financial results will be held on July 30, 2025, at 8:30 a.m. Eastern Time, featuring key executives including the CEO, CFO, and CTO [4][5]. - Participants are encouraged to pre-register for the call to receive unique dial-in information [5]. Company Overview - InMode is a global provider of innovative medical technologies, focusing on devices that utilize novel radio frequency technology for various medical applications [7][8]. - The company aims to enhance surgical procedures and improve existing treatments through its minimally invasive RF technologies [8].

Financial Performance & Outlook - Cerus achieved positive non-GAAP adjusted EBITDA for Q4 and full year 2024 [9] - The company anticipates product revenue growth of 8% to 11% year-over-year in 2025 [9] - Cerus is committed to sustaining positive adjusted EBITDA for fiscal year 2025 [9] - GAAP net loss attributable to Cerus improved by over 40% in 2024 compared to 2023 [9] - In 2024, Cerus achieved 15% topline growth due to strong team performance and blood center partnerships [10] Market & Product Expansion - Cerus is focused on the continued global expansion of its platelet franchise [9] - The company expects increasing uptake of INTERCEPT Fibrinogen Complex (IFC) in the US [9] - The global addressable market for INTERCEPT products is currently $1.3 billion and is expected to grow to over $1.5 billion in the next 5-7 years [16] - The U S addressable market is $150 million and is expected to grow to over $200 million in the next 5-7 years [16] Technology & Impact - Cumulative kit sales for over 16 million INTERCEPT treated doses of platelets & plasma [5]

Core Viewpoint - Enovis Corporation will host an investor conference call and live webcast to discuss its second quarter 2025 financial results on August 7, 2025, at 8:30 a.m. Eastern Time, with an earnings press release issued earlier that morning [1]. Group 1: Conference Call/Webcast Information - Investors can access the live webcast via a link on the Enovis website, and those participating in the call can dial (833) 685-0901. A replay of the call will be available on the Enovis website later that day [2]. Group 2: Company Overview - Enovis Corporation is an innovation-driven medical technology growth company focused on developing clinically differentiated solutions that improve patient outcomes and transform workflows. The company offers a wide range of products, services, and integrated technologies aimed at supporting active lifestyles in orthopedics and beyond [3]. Group 3: Information Availability - Enovis routinely announces material information to investors and the marketplace through SEC filings, press releases, public conference calls, webcasts, and its Investor Relations website. The company encourages stakeholders to review the information shared on its Investor Relations site [4].

Core Viewpoint - Medtronic plc has appointed Chad Spooner as the chief financial officer (CFO) of MiniMed, ahead of its planned separation into a standalone public company, effective July 14, 2025 [1][5]. Company Overview - Medtronic is a global leader in healthcare technology, headquartered in Galway, Ireland, with a mission to alleviate pain, restore health, and extend life [8]. - The company employs over 95,000 people across more than 150 countries and addresses 70 health conditions through various technologies and therapies [8]. Leadership Appointment - Chad Spooner brings over 25 years of financial leadership experience in healthcare, consumer, and industrial sectors, previously serving as CFO at BIC and holding senior finance roles at General Electric and other companies [2][4]. - His appointment is seen as crucial for driving transformation and growth as MiniMed prepares for independence [3][4]. MiniMed Separation - Medtronic announced that MiniMed will be the name of the new standalone company, honoring its 40-year legacy in diabetes care [3]. - The separation is expected to be completed within 18 months of the initial announcement, subject to customary conditions and legal requirements [5]. Mission and Vision - MiniMed's mission is to make diabetes management more predictable, enhancing the lives of individuals with diabetes through advanced technology and support [7].